ASTHMA & RESPIRATORY DISORDERS (PAR)
PAR1	COST OF ASTHMA IN CHILDREN IN VLADIVOSTOK Prosekova E1, Geltzer B2, Dercach V1, Bogdanovskiy P2, 1Child's Municipal Asthma-centre, Vladivostok, Russia; 2Vladivostok State Medical University, Vladivostok, Russia
PAR2	USE OF RESPIRATORY ASSIST DEVICES BY MEDICARE BENEFICIARIES Silverman BG, Health Care Financing Administration, Baltimore, MD, USA
PAR3	THE STANDARDIZED ASTHMA-RELATED QUALITY OF LIFE QUESTIONNAIRE (AQLQ-S): DOES SOCIOECONOMIC STATUS EFFECT MEASUREMENTS? Lynd LD1, Guh D2, Pare P2, Anis A1, 1University of British Columbia, Vancouver, BC, Canada; 2Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada
PAR4	COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Aubert RE, Alemayehu B, Feifer R, Merck-Medco Managed Care, Franklin Lakes, NJ, USA
PAR5	DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS Birnbaum HG1, Morley MA1, Greenberg PE1, Cifaldi M2, Colice GL3, 1Analysis Group/Economics, Cambridge, MA, USA; 2Independent Consultant, Leawood, KS, USA; 3Washington Hospital Center, Washington, DC, USA
PAR6	PROPHYLACTIC MEDICATION UTILIZATION AND HEALTH CARE COSTS IN OLDER ADULTS WITH CHRONIC PULMONARY AILMENTS Balkrishnan R1, Christensen D2, Bowton D1, 1Wake Forest University School of Medicine, Winston-Salem, NC, USA; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
PAR7	VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE Sullivan P, Nichol M, University of Southern California, Los Angeles, CA, USA
PAR8	A COST-EFFECTIVENESS ANALYSIS COMPARING LEVALBUTEROL AND ALBUTEROL IN THE TREATMENT OF MODERATE TO SEVERE ASTHMA Carter CT, McGee MD, Northeastern University, Boston, MA, USA
PAR9	VALIDATION OF A RATING INSTRUMENT ASSESSING THE INHALATION SKILLS OF CHILDREN WITH ASTHMA Pradel FG, Weiss S, Tsoukleris M, Bollinger MB, Fahlman C, University of Maryland, Baltimore, MD, USA
PAR10	IMPLEMENTING RASCH ANALYSIS IN PSYCHOMETRIC EVALUATION OF PATIENT-PHYSICIAN INTERACTION SCALE Dalal M, Smith E, Lambert B, Olopade C, University of Illinois at Chicago, Chicago, IL, USA
PAR11	THE LONG-TERM SOCIETAL ECONOMIC AND HUMANISTIC BENEFITS OF TREATING ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) WITH GEMIFLOXACIN VERSUS LARITHROMYCIN Halpern M1, Kirsch JM2, Palmer C3, Zodet M3, Wilson R4, 1Charles River Associates, Washington, DC, USA; 2GlaxoSmithKline, Harlow, UK; 3MEDTAP International, Bethesda, MD, USA; 4Royal Brompton Hospital, London, UK
PAR12	PROSPECTIVE USE OF WEB BASED TECHNOLOGY TO EVALUATE HEALTH OUTCOMES IN A LARGE COHORT OF SEVERE OR DIFFICULT TO TREAT ASTHMATICS Dolan CM1, Fisher KA1, Johnson C1, Fraher KE1, Rothermich EA2, Fine JT1, Weiss ST3, Wenzel S4, 1Genentech, Inc, South San Francisco, CA, USA; 2The Lewin Group, San Francisco, CA, USA; 3Harvard University, Boston, MA, USA; 4National Jewish Medical and Research Center, Denver, CO, USA
PAR13	HYPOTHETICAL VERSUS REAL WILLINGNESS TO PAY IN THE HEALTH CARE SECTOR: RESULTS FROM A FIELD EXPERIMENT Blumenschein K1, Johannesson M2, Yokoyama K3, Freeman P4, 1University of Kentucky College of Pharmacy and Martin School of Public Policy and Administration, Lexington, KY, USA; 2Stockholm School of Economics, Stockholm, Sweden; 3Scott & White Memorial Hospital Department of Pharmacy, Temple, TX, USA; 4American Pharmacy Services Corporation, Frankfort, KY, USA
PAR14	ASSESSMENT OF THE RELATIONSHIP BETWEEN DISEASE SEVERITY, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA Zillich A1, Blumenschein K1, Johannesson M2, Freeman P3, 1University of Kentucky College of Pharmacy, Lexington, KY, USA; 2Stockholm School of Economics, Stockholm, Sweden; 3American Pharmacy Services Corporation, Frankfort, KY, USA
PAR16	COMPARISON OF HEALTHCARE RESOURCE UTILIZATION OF COPD PATIENTS ON CILOMILAST, 15 MG BID VERSUS PLACEBO Bagchi I, Bakst A, Edelson J, Amit O, GlaxoSmithKline, Collegeville, PA, USA
PAR16	COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION Armstrong EP, Malone DC, Rehfeld RA, University of Arizona, Tucson, AZ, USA
PAR18	PATIENT SATISFACTION WITH NON-SEDATING ANTIHISTAMINES Sahu S, Millard R, Harris Interactive, Rochester, NY, USA
PAR18	COSTS OF TREATING COPD IN ITALY: A BURDEN OF ILLNESS STUDY Bonzanini A, Avossa R, Scipioni E, Gianfrate F, GlaxoSmithKline, Verona, Italy
PAR19	IMPACT OF THE ADDITION OF SALMETEROL TO THE TREATMENT OF ASTHMA PATIENTS IN A MEDICAID FEE-FOR-SERVICE POPULATION Klaurens LM, Dodd MA, Gupchup GV, Kelly HW, Hollarbush J, The University of New Mexico, Albuquerque, NM, USA
PAR20	EFFECTIVENESS OF COMPLIANCE ON HEALTHCARE RESOURCE USE IN ASTHMA PATIENTS TREATED WITH MONTELUKAST VS. INHALED CORTICOSTEROIDS Kutikova L1, Bowman L2, Morris L3, 1University of Tennessee Health Science Center, Memphis, TN, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3IMS Health, Plymouth Meeting, PA, USA
PAR21	LEVALBUTEROL USE IS ASSOCIATED WITH DECREASED HEALTHCARE COSTS IN PATIENTS WITH MORE SEVERE ASTHMA Huse D1, McLoney A2, Yeager B3, Cerasoli F3, 1PharMetrics, Inc, Watertown, MA, USA; 2NDC Health Information Services, Phoenix, AZ, USA; 3Sepracor, Inc, Marlborough, MA, USA
PAR22	IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES Huse D1, McLoney A2, Yeager B3, Cerasoli F3, 1PharMetrics, Inc, Watertown, MA, USA; 2NDC Health Information Services, Phoenix, AZ, USA; 3Sepracor, Inc, Marlborough, MA, USA
PAR23	DETERMINANTS OF INAPPROPRIATE ANTIBIOTIC PRESCRIBING Willis MK, NJ Carpenters Funds, Edison, NJ, USA

CANCER (PCN)
PCN1	CATEGORIZATION OF RISK OF PROSTATE CANCER: PILOT TEST OF CLINICAL OUTCOMES AND RISK PERCEPTIONS Bruner DW, Parlanti AA, Ross E, Raysor S, Mazzoni SE, Hanks GE, Fox Chase Cancer Center, Philadelphia, PA, USA
PCN2	WHICH VARIABLES DO METASTATIC BREAST CANCER PATIENTS AND ONCOLOGY NURSES ANCHOR ON WHEN USING THE EUROQOL DESCRIPTIVE SYSTEM IN MEASURING UTILITIES WITH THE STANDARD GAMBLE TECHNIQUE Hauser R12, Koeller J1, 1University of Texas at Austin, Austin, TX, USA; 2Abt Associates Clinical Trials, Cambridge, MA, USA
PCN3	PREDICTORS OF CHEMOTHERAPY-RELATED NEUTROPENIA: A REVIEW OF THE CLINICAL LITERATURE Palmer C1, Brown R1, Wilson-Royalty M2, Lawless G2, 1MEDTAP International Inc, Bethesda, MD, USA; 2Amgen, Inc, Thousand Oaks, CA, USA
PCN4	COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES Gagnon DD1, Martin SC1, van Hout B2, 1The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA; 2Utrecht University, Utrecht, Netherlands
PCN5	DOCETAXEL/DOXORRUBICIN (DD) AS FIRST LINE CHEMOTHERAPY: QUALITY OF LIFE (QOL) IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) Bonicatto SC, FUNDONAR Foundation, La Plata, Argentina
PCN6	CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS? Thomas SK, Brooks SE, Mullins CD, University of Maryland, Baltimore, MD, USA
PCN7	ECONOMIC EVALUATION OF GEMZAR AND BEST SUPPORTIVE CARE (BSC) RELATIVE TO BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK McKendrick J1, Botwood N1, Aristides M2, Lees M2, Maniadakis N3, Wein W3, Stephenson D1, 1Eli Lilly, Basingtsoke, Hampshire, UK; 2M-TAG, London, UK; 3Eli Lilly, Windlesham Surrey, UK
PCN8	ECONOMIC EVALUATION OF GEMZAR IN THE TREATMENT OF PANCREATIC CANCER IN THE UK Stephenson D1, Botwood N1, McKendrick J1, Aristides M2, Lees M2, Maniadakis N3, Wein W3, 1Eli Lilly, Basingstoke, UK; 2M-TAG, London, UK; 3Eli Lilly, Windlesham Surrey, UK
PCN9	ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK Lees M1, Aristides M1, Botwood N2, McKendrick J2, Maniadakis N3, Wein W3, Stephenson D2, 1M-TAG, London, UK; 2Eli Lilly, Basingtsoke, Hampshire, UK; 3Eli Lilly, Windlesham Surrey, UK
PCN10	COST-EFFECTIVENESS MODEL OF PROSTATE-SPECIFIC ANTIGEN (PSA) SCREENING FOR PROSTATE CANCER Sokolskiy L, Hay JW, University of Southern California, Los Angeles, CA, USA
PCN11	ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK Smith DH1, Drummond MF2, Johnston S3, Gordon A4, 1Kaiser Permanente Center for Health Research, Portland, OR, USA; 2University of York, York, UK; 3Royal Marsden Hospital and Institute of Cancer Research, London, UK; 4Sammons Cancer Center, U S Oncology, Dallas, TX, USA
PCN12	COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER Hauser R13, Theriault R2, Shepherd M3, Lawson K3, Wilson J3, Koeller J3, 1Abt Associates Clinical Trials, Cambridge, MA, USA; 2University of Texas M.D.Anderson Cancer Center, Houston, TX, USA; 3University of Texas, Austin, TX, USA
PCN13	COST OF THROMBOCYTOPENIA-RELATED BLEEDING AMONG PATIENTS WITH CANCER Elting LS, Martin CG, Hamblin L, Chau Q, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
PCN14	CHOICE OF LOCALIZED BREAST CANCER TREATMENTS IN A MEDICARE POPULATION: A COMPARISON OF OUTCOMES AND COSTS Polsky D1, Venditti L1, Mandelblatt JS2, Weeks JC3, Hadley J4, Hwang YT2, Schulman K5, 1University of Pennsylvania, Philadelphia, PA, USA; 2Georgetown University, Washington, DC, USA; 3Harvard Medical School, Boston, MA, USA; 4The Urban Institute, Washington, DC, USA; 5Duke University Medical Center, Durham, NC, USA
PCN15	DIFFERENCES BETWEEN PREFERENCES FOR HEALTH STATES: THE CHEMOTHERAPY ADVERSE EVENT SELF-ASSESSED RESPONSE (CAESAR) QUESTIONNAIRE Purdum AG1, Globe D2, Mathes A3, Nichol MB2, 1Protocare Sciences, Santa Monica, CA, USA; 2University of Southern California, Los Angeles, CA, USA; 3Independent Health Outcomes Consultant, Odessa, FL, USA
PCN16	CHEMOTHERAPY TREATMENT IN NEWLY DIAGNOSED BREAST CANCER PATIENTS IN A MANAGED CARE POPULATION Yazdani C1, McLaughlin T1, Koos F2, Hansen J1, 1NDC Health, Phoenix, AZ, USA; 2PharMetrics, Inc, Watertown, MA, USA
PCN17	AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF ADVANCED COLORECTAL CANCER IN THE UK Sorensen S1, Brown R1, De Cock E1, Bearne A2, 1MEDTAP International Inc, Bethesda, MD, USA; 2Aventis Pharma, Kent, UK
PCN18	COLORECTAL CANCER SCREENING: AWARENESS, UTILIZATION, AND BARRIERS Straus W1, Schaffner P1, Gold K2, Pashos C3, Mansley E1, 1Merck & Co., Inc, West Point, PA, USA; 2Abt Associates Inc, Cambridge, MA, USA; 3Abt Associates Clinical Trials, Cambridge, MA, USA
PCN19	COlorectal cancer screening tests: variation in preferences based on gender and race Straus W1, Schaffner P1, Gold K2, Pashos C3, Mansley E1, 1Merck & Co., Inc, West Point, PA, USA; 2Abt Associates Inc, Cambridge, MA, USA; 3Abt Associates Clinical Trials, Cambridge, MA, USA
PCN20	COST MINIMIZATION ANALYSIS OF CEFEPIME VERSUS IMIPENEM-CILASTATINE IN CANCER PATIENTS WITH SHORT-DURATION FEBRILE NEUTROPENIA Vorobjov P, Fisenko V, Gerasimov V, Avxentieva M, Moscow Medical Academy, Moscow, Russia
PCN21	HEALTH-RELATED QUALITY OF LIFE AFTER ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER Lubeck DP, Grossfeld GD, Carroll PR, University of California-San Francisco, San Francisco, CA. USA
PCN22	COST-EFFECTIVENESS ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER Hauser R12, Koeller J1, 1University of Texas at Austin, Austin, TX, USA; 2Abt Associates Clinical Trials, Cambridge, MA, USA
PCN23	DISEASE MODELING: DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL Becker RV1, Noe L1, Gore M2, Martino S3, Eiermann W4, Namer M5, Howell A6, Bianco A7, Watanabe T8, 1Ovation Resarch Group, Highland Park, IL, USA; 2Avalon Health Solutions, Wilmington, DE, USA; 3John Wayne Cancer Institute, Santa Monica, CA, USA; 4Rot-Kreuz-Hospital, Munich, Germany; 5Centre Antoine Lacassagne, Nice, France; 6Christie Hospital, Manchester, UK; 7University Frederico II Department of Medical Oncology, Naples, Italy; 8National Cancer Center Hospital, Tokyo, Japan
PCN24	INCIDENCE AND COST OF HOSPITALIZATION FOR 5-FU TOXICITY AMONG MEDICARE BENEFICIARIES WITH METASTATIC COLORECTAL CANCER Delea TE1, Vera-Llonch M1, Edelsberg JS1, McGarry L2, Anton S3, Ulcickas-Yood M4, Oster G1, 1Policy Analysis Inc, Brookline, MA, USA; 2Innovus Research Inc, Medford, MA, USA; 3Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 4Bristol Myers Squibb, Wallingford, CT, USA
PCN25	A QUALITY OF LIFE AUDIT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING CHEMOTHERAPY AT ONE INSTITUTION Musgrave KR, Wyld D, Abraham R, The Prince Charles & Royal Brisbane Hospitals, Brisbane, Australia
PCN26	SYSTEMATIC ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER Huang JC, Veenstra DL, University of Washington, Seattle, WA, USA
PCN27	COST OF TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN THE UNITED STATES Cronin K, Lee B, Wang D, The Lewin Group, Falls Church, VA, USA
PCN28	DETECTING RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER IN CLINICAL PRACTICE: NEED FOR A CHANGE? Hooft L, Hoekstra OS, University Hospital Vrije Universiteit, Amsterdam, Netherlands

CARDIOVASCULAR DISEASE (PCV)
PCV1	A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN AS PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH ESTABLISHED PERIPHERAL ARTERY DISEASE Decerbo MC, Baroletti SA, Isopo S, Silva M, Talati DK, Northeastern University, Boston, MA, USA
PCV2	VENOUS THROMBOEMBOLIC (VTE) COMPLICATIONS FOLLOWING MAJOR ORTHOPEDIC SURGERY: FREQUENCY AND ECONOMIC CONSEQUENCES IN HOSPITAL Gabriel S1, Dinet J1, Dispot T2, Radal C2, 1Sanofi-Synthelabo, Bagneux, France; 2Medcost, Paris, France
PCV3	AN ANALYSIS OF THE COST OF ADVERSE EVENTS ASSOCIATED WITH THE USE OF HMG-COA REDUCTASE INHIBITORS McBurney CR12, Smith D2, 1Pfizer Inc., Ann Arbor, MI, USA; 2University of Michigan, Ann Arbor, MI, USA
PCV4	ASSESSING QUALTIY OF LIFE IN PATIENTS SIX MONTHS AFTER A MYOCARDIAL INFARCTION USING THE SF-12 McBurney CR12, Erickson SR2, Kline-Rogers EM2, Cooper JV2, Mani OCM2, Eagle KA2, 1Pfizer Inc. Ann Arbor, MI, USA; 2University of Michigan, Ann Arbor, MI, USA
PCV5	COST OF TREATMENT AND PREVALENCE OF CARDIOVASCULAR DISEASE COMORBIDITIES AND RISK FACTORS IN THE SEVERE AND PERSISTENTLY MENTALLY ILL Bellnier TJ1, Labrum A2, Karki SD1, Sundberg J2, 1SUNY University at Buffalo, School of Pharmacy, Buffalo, NY, USA; 2University of Rochester, Rochester, NY, USA
PCV6	ESTIMATING INCREMENTAL COSTS FOR ADDITIONAL HOSPITAL DAYS Friedman JY1, Reed SD1, Gnanasakthy A2, Schulman KA1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis Pharmaceutical Corp, East Hanover, NJ, USA
PCV7	COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION McGhan WF, University of the Sciences, Philadelphia, PA, USA
PCV8	PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS: DATABASE ANALYSIS IN FRANCE Baptiste C1, Guilhaume C2, 1G.Y.D. institute, Lyon, France; 2Sanofi-Synthelabo, Bagneux, France
PCV9	AN ECONOMIC ANALYSIS OF CONGESTIVE HEART FAILURE (CHF) IN THE LOUISIANA MEDICAID PROGRAM Ogale SS, Blake SG, Biglane GC, Medon PJ, The University of Louisiana at Monroe, Monroe, LA, USA
PCV10	INCIDENCE OF RHABDOMYOLYSIS IN PATIENTS INITIATED ON HMG CO-A REDUCTASE INHIBITOR THERAPY IN A MANAGED CARE ORGANIZATION White TJ, Chang EY, Prescription Solutions, Costa Mesa, CA, USA
PCV11	COST OF WARFARIN TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abdelhafiz AH, Wheeldon N, Sheffield University, Sheffield, UK
PCV12	QUALITY OF CARE IN OLDER PATIENTS ADMITTED TO HOSPITAL WITH HEART FAILURE Abdelhafiz AH, Wheeldon N, Sheffield University, Sheffield, UK
PCV13	IMPACT ON QUALITY ADJUSTED LIFE YEARS OF ENOXAPARIN FOR PREVENTING THROMBOSIS AMONG HOSPITALIZED MEDICAL PATIENTS Raisch DW1, Fye CL1, Sather MR1, Henderson WG2, Reda DJ2, Sacks JM2, Lederle FL3, 1Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA; 2Veterans Affairs Cooperative Studies Program, Chicago, IL, USA; 3VA Medical Center, Minneapolis, MN, USA
PCV14	IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): AN ANALYSIS OF BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA Hassan M, Joshi AV, Madhavan S, Amonkar M, West Virginia University School of Pharmacy, Morgantown, WV, USA
PCV15	ECONOMIC EVALUATION OF OUTPATIENT ANTICOAGULANT/ANTIPLATELET THERAPY FOLLOWING CORONARY STENTING IN A MANAGED CARE POPULATION Liao E, Fronk M, Newell J, Huse D, PharMetrics, Inc, Watertown, MA, USA
PCV16	COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME PATIENTS IN POLAND Orlewska E1, Budaj A2, Tereszkowski-Kaminski D3, 1Medical University of Warsaw, Warsaw, Poland; 2Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland; 3Uniformed Services Health Fund, Warsaw, Poland
PCV17	QUALITY OF LIFE AND PATIENT PREFERENCE AS PREDICTORS FOR RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE; INTERIM ANALYSIS Shin GP1, Tooley JF2, Southworth MR1, Dunlap S1, Boyer JG2, Johnson NE1, 1University of Illinois at Chicago, Chicago, IL, USA; 2Pharmacia, Skokie, IL, USA
PCV18	FRAMINGHAM RISK EQUATIONS PREDICT HOSPITAL USAGE AND MORTALITY Milne RJ, Gamble GD, Whitlock G, Jackson RT, University of Auckland, Auckland, New Zealand
PCV19	DISCRIMINABILITY FOR RISK OF CARDIOVASCULAR EVENTS Milne RJ, Gamble GD, Whitlock G, Irwin RJ, Jackson RT, University of Auckland, Auckland, New Zealand
PCV20	ASSESSING THE TOTAL COST OF MANAGEMENT OF A PATIENT WITH DEEP VEIN THROMBOSIS (DVT) IN FRANCE AND IN ITALY Levy E1, Gabriel S2, Dinet J2, Rudelli G3, 1University Paris-Dauphine, Paris, France; 2Sanofi-Synthelabo, Bagneux, France; 3Sanofi-Synthelabo SPA, Milano, Italy
PCV21	COST-EFFECTIVENESS ANALYSIS OF ABCIXIMAB, EPTIFIBATIDE, AND TIROFIBAN IN PATIENTS WITH CORONARY SYNDROMES Shahriar J, Shaw JW, Malone D, The University of Arizona, Tucson, AZ, USA
PCV22	IN-PATIENT AND OUT-PATIENT RESOURCE UTILIZATION AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE - THE VA EXPERIENCE L'Italien GJ1, Williams LS2, Weinberger M2, 1Bristol-Myers Squibb, Wallingford, CT, USA; 2Roudebush Veterans Affairs Medical Center, Indiana University School of Medicine, Regenstrief Institute for Health Care, Indianapolis, IN, USA
PCV23	PHARMACOECONOMIC EVALUATION OF USAGE OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS IN LONG TERM CARE RESIDENTS Karki SD1, Bellnier TJ1, Karki J1, Patterson W2, Masood R2, 1SUNY University at Buffalo, School of Pharmacy, Buffalo, NY, USA; 2Clifton Springs Hospital & Clinics, Clifton Springs, NY, USA
PCV24	BEYOND THE FIRST YEAR: PATTERNS AND PREDICTORS OF LONG-TERM STATIN UTILIZATION Benner JS1, Federman AD1, Smitten AL2, Duty S2, Glynn RJ1, Avorn J1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 2Harvard School of Public Health, Boston, MA, USA
PCV25	CHD RISK FACTORS AND THERAPY DURATION OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN A MEDICAID POPULATION Nichol MB1, Bron MS1, Yu W2, 1University of Southern California, Los Angeles, CA, USA; 2Wellpoint Pharmacy Management, Thousand Oaks, CA, USA
PCV26	CARING FOR HYPERTENSION ON INITIATION: COSTS AND EFFECTIVENESS (CHOICE). DESIGN AND RATIONALE OF A NATURALISTIC STUDY Payne K1, Caro J1, Hollenberg N2, Jackson J3, L'Italien G3, for the CHOICE Study Group, 1Caro Research Institute, Dorval, QC, Canada; 2Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; 3Bristol-Myers Squibb, Princeton, NJ, USA
PCV27	A PHARMACOECONOMIC MODEL TO EVALUATE TREATMENT OPTIONS FOR DVT PHARMACOPROPHYLAXIS Spruill WJ, Wade WE, Leslie RB, University of Georgia College of Pharmacy, Athens, GA, USA
PCV28	CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER Graff JS12, Plante M1, Smith D2, 1Pfizer Inc, Ann Arbor, MI, USA; 2University of Michigan, Ann Arbor, MI, USA
PCV29	ECONOMIC OUTCOMES OF PATIENTS RECEIVING CARVEDILOL COMPARED TO THOSE RECEIVING NO BETA-BLOCKER THERAPY FOR THE TREATMENT OF CONGESTIVE HEART FAILURE IN A MANAGED CARE ORGANIZATION White TJ, Chang EY, Leslie RS, Jackson AJ, Prescription Solutions, Costa Mesa, CA, USA
PCV30	COST EFFECTIVENESS MODEL OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION Mulani P, Hay J, University of Southern California, Los Angeles, CA, USA
PCV31	CLOSURE OF ATRIAL SEPTAL DEFECT: MEDICO-ECONOMIC ARGUMENTS TO CHOOSE BETWEEN INVASIVE SURGERY AND PERCUTANEOUS TECHNIQUE USING SEPTAL OCCLUDER Laroche S, Allenet B, Foroni L, Calop J, CAMSP - CHU Grenoble, Grenoble, France
PCV32	STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS Coombs JH13, Cornish L2, Hiller P2, Smith DG3, 1Pfizer, Ann Arbor, MI, USA; 2M-CARE, Ann Arbor, MI, USA; 3University of Michigan, Ann Arbor, MI, USA
PCV33	COST-ANALYSIS OF CABG SURGERY IN PATIENTS WITH AND WITHOUT RETHORACOTOMY FROM THE HOSPITAL PERSPECTIVE IN GERMANY Spannheimer A1, Mast O2, Schlereth T1, Thate-Waschke IM2, Dietrich W3, 1Kendle International Inc, Munich, Germany; 2Bayer Vital GmbH & Co KG, Leverkusen, Germany; 3Deutsches Herzzentrum, Munich, Germany
PCV34	DECISION ANALYSIS MODEL OF ABCIXIMAB, EPTIFIBATIDE OR STANDARD THERAPY IN ELECTIVE STENT PLACEMENT: A CANADIAN PERSPECTIVE Sridhar K, Gwadry F, Kidwai B, Almond D, Teefy P, London Health Sciences Centre, London, ON, Canada
PCV35	COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY: DO THE RESULTS HELP THE DECISION-MAKING PROCESS? Mullins CD1, Akhras KS2, Blak B1, 1University of Maryland, Baltimore, MD, USA; 2Pharmacia Corporation, Skokie, IL, USA
PCV36	EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATA Coombs JH13, Cornish L2, Hiller P2, Smith DG3, 1Pfizer, Ann Arbor, MI, USA; 2M-CARE, Ann Arbor, MI, USA; 3University of Michigan, Ann Arbor, MI, USA
PCV37	THE COST-EFFECTIVENESS OF STATINS: EVIDENCE FROM THE ACCESS TRIAL Smith DG, University of Michigan, Ann Arbor, MI, USA
PCV38	A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF SIBUTRAMINE AND ORLISTAT FOR THE MANAGEMENT OF OBESITY O'Meara S1, Riemsma R1, Shirran L2, Mather L1, ter Riet G3, 1University of York, York, UK; 2University of Aberdeen, Aberdeen, UK; 3Univerisity of Maastricht, Maastricht, Netherlands
PCV39	COST OF TREATMENT OF HYPERCHOLESTEROLAEMIA TO NHF GOALS IN AUSTRALIA Wlodarczyk J1, Barter PJ2, O'Brien R3, Talmont D4, Ortiz M4, 1John Wlodarczyk Consulting Services, Newcastle, NSW, Australia; 2Royal Adelaide Hospital, Adelaide, Australia; 3Monash Medical Centre, Melbourne, Australia; 4Pfizer Pty Ltd, Sydney, Australia
PCV40	COST-EFFECTIVENESS OF LIPID LOWERING INTERVENTIONS IN A NATIVE AMERICAN CARDIOVASCULAR RISK REDUCTION PROGRAM Kumar RN1, Borrego ME2, Gupchup GV2, Anderson JR2, Burden RW3, Phillips DL3, 1University of Michigan, Ann Arbor, MI, USA; 2University of New Mexico, Albuquerque, NM, USA; 3Santa Fe Indian Hospital, Santa Fe, NM, USA
PCV41	SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442 - ONE-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY Pfeil T1, Rychlik R1, Daniel D1, Habs M2, Klapper HG2, Böhm M3, 1Institute of Empirical Health Economics, Burscheid, Germany; 2Dr. Willmar Schwabe Arzneimittel, Karlsruhe, Germany; 3Medizinische Klinik u. Poliklinik, Bad Homburg, Germany
PCV42	PATIENTS' WILLINGNESS TO PAY FOR PHARMACIST MANAGED WARFARIN THERAPY AT COMMUNITY PHARMACIES Wong PK, Jang R, University of Cincinnati, Cincinnati, OH, USA
PCV43	PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS: DATABASE ANALYSIS IN FRANCE Baptiste C1, Guilhaume C2, 1G.Y.D. Institute, Lyon, France; 2Sanofi-Synthelabo, Bagneux, France

DIABETES (PDB)
PDB1	DIABETIC MANAGEMENT THROUGH ORAL GLUCOSE LOWERING AGENTS: TREATMENT PATTERN , COST AND UTILIZATION ANALYSIS Thompson FD1, Rosenblum MS2, O'Neill JM2, Celebi D1, Olmsted E1, 1IHCIS, Lexington, MA, USA; 2Integrail, Latham, NY, USA
PDB2	USING RETROSPECTIVE CLAIMS DATA TO DESIGN CLINICAL SAFETY SURVEILLANCE OF THIAZOLIDINEDIONE DRUGS Henriques C1, Schultz D2, Milanette T1, Todoroff K1, Kim M1, 1Solucient, Waltham, MA, USA; 2Solucient, Ann Arbor, MI, USA
PDB3	THE BURDEN OF ILLNESS OF DIABETES MELLITUS TYPE 2 IN GERMANY - A PILOT STUDY Tepe M1, Kilburg A2, Daniel D2, Kirchhoff D2, Rychlik R2, 1Novartis Pharma GmbH, Nuremberg, Germany; 2Institute of Empirical Health Economics, Burscheid, Germany
PDB4	COST-EFFECTIVENESS AND CARDIOVASCULAR RISK - AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS Oh PI1, Shane LG2, 1Sunnybrook and Women's College Health Science Centre, Toronto, ON, Canada; 2GlaxoSmithKline Beecham, Mississuaga, ON, Canada
PDB5	A COST-MINIMIZATION STUDY TO DETERMINE THE IMPACT OF ADDING GLUCOVANCE TO A COUNTY HOSPITAL FORMULARY Lal LS1, Ogbonnaya KI2, 1Texas Southern University - College of Pharmacy, Houston, TX, USA; 1Baylor College of Medicine, Houston, TX, USA
PDB6	AN EARLY LOOK AT TZD USE AMONG TYPE 2 DIABETES PATIENTS Schabert VF1, Guo M2, Conklin JE1, Neslusan CA2, 1The MEDSTAT Group, Santa Barbara, CA, USA; 2R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
PDB7	COSTS AND EFFECTIVENESS OF INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES Hisashige A, Katayama T, Mikasa H, University of Tokushima, School of Medicine, Tokushima, Japan
PDB8	FACTORS ASSOCIATED WITH PRESCRIPTION CLAIMS FOR BLOOD GLUCOSE TEST STRIPS AMONG FEE-FOR-SERVICE NEW MEXICO MEDICAID PATIENTS Cordova CJ, Shah BM, Dodd MA, Gupchup GV, The University of New Mexico, Albuquerque, NM, USA
PDB9	COST-EFFECTIVENESS ANALYSIS OF A MULTIDISCIPLINARY DIABETES CARE CLINIC Yokoyama KK, Griffin KC, Godley PJ, Cryar AK, Woodward BW, Scott & White Memorial Hospital, Temple, TX, USA
PDB10	THE COST OF NEW ONSET DIABETES MELLITUS AMONG US RENAL TRANSPLANT RECIPIENTS Woodward RS1, Schnitzler MA1, Lowell JA1, Haider S2, Brennan DC1, 1Washington University, St. Louis, MO, USA; 2Pfizer, Inc, Groton, CT, USA
PDB11	ECONOMIC OUTCOMES OF DIABETES AMONG AN EMPLOYED POPULATION Leong SA1, Summers KH2, Birnbaum HG1, Kemner JE2, Lentz EC1, Greenberg PE1, 1Analysis Group/Economics, Cambridge, MA, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
PDB12	A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE Lee KK, You JH, Ho SS, Leung WY, Thomas G, Chan TY, Critchley J, The Chinese University of Hong Kong, Hong Kong, China
PDB13	OPTIMIZATION OF DIABETES MANAGEMENT IN GERMANY USING A COMPUTER BASED OUTCOME PROGNOSES MODEL Brandt A, Gozzoli V, Palmer A, Weiss C, Neeser K, Schramm W, Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland
PDB14	IMPACT OF A DIABETES DISEASE MANAGEMENT PROGRAM: A RETROSPECTIVE CLAIMS-BASED EVALUATION Berger J, Slezak J, O'Leary W, McStay P, Johnson K, Addiego J, Caremark Inc, Northbrook, IL, USA
PDB15	DOES PATIENT EXPERIENCE MATTER?: TYPE II DIABETES PATIENTS' STATED PREFERENCES FOR INSULIN THERAPIES Ginger S1, Bingham M1, Johnson FR1, Bolinder B2, 1Triangle Economic Research, Durham, NC, USA; 2Aventis Pharmaceuticals, Bridgewater, NJ, USA
PDB16	AN OVERVIEW OF PHARMACOECONOMICS IN TURKEY: COST ANALYSIS AND REIMBURSEMENT OF ANTIDIABETIC DRUGS Sapci AH1, Sapci HA2, Demirdamar R3, 1Numune Research Hospital, Ankara, Turkey; 2Faculty of Medicine, Gazi University, Ankara, Turkey; 3Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

EYE/EAR/SKIN/DENTAL (PEE)
PEE1	ANTIBIOTIC PRESCRIBING PATTERNS FOR THE TREATMENT OF INITIAL ACUTE OTITIS MEDIA IN CHILDREN ENROLLED IN IOWA MEDICAID FROM 1990 THROUGH 1997 Park TR, Brooks JM, University of Iowa, Iowa City, IA, USA
PEE2	THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYER'S PERSPECTIVE Higashi MK1, Veenstra D1, del Aguila M2, Hujoel P1, 1University of Washington, Seattle, WA, USA; 2Washington Dental Service, Seattle, WA, USA
PEE3	DRY-EYE RELATED INCREASES IN HEALTH CARE UTILIZATION AND EXPENDITURES Smeeding JE14, McLaughlin T2, Yazdani C2, Walt JG3, 1PharMetrics, Athens, GA, USA; 2NDC Health Information Services, Phoenix, AZ, USA; 3Allergan, Irvine, CA, USA; 4University of Texas, Athens, GA, USA
PEE4	THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX Finlay A1, Corvest M2, Lefrançois P3, Taieb C4, 1University of Wales College of Medicine, Cardiff, UK; 2Association Pour La Lutte Contre Le Psoriasis, Eragny, France; 3Pierre Fabre Dermatologie, Lavaur, France; 4PharmacoEconomics Programs, Pierre Fabre SA, Boulogne Billancourt, France
PEE5	INAPPROPRIATE ANTIBIOTIC PRESCRIBING AND ECONOMIC OUTCOMES FOR PEDIATRIC OTITIS MEDIA Rahman AM1, Feldhaus J2, Lawrence L2, Rappaport H2, Moser E2, 1St. John's University, Jamaica, NY, USA; 2University of Louisiana at Monroe, Monroe, LA, USA
PEE6	COST-EFFECTIVENESS OF ARTIFICIAL SKIN SUBSTITUTE VS ALLOGRAFT FOR BURN PATIENTS Bron MS, Hay J, University of Southern California, Los Angeles, CA, USA
PEE7	A COST COMPARISON STUDY OF COMMON PRACTICE AND BEST PRACTICE TREATMENT FOR PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES Evans SJ1, Casciano J1, Doyle JJ1, Walt JG2, 1The Analytica Group, New York, NY, USA; 2Allergan, Irvine, CA, USA
PEE8	FOUR YEAR COST-EFFECTIVENESS OF INITIAL TRABECULECTOMY VERSUS CONVENTIONAL THERAPY IN PRIMARY OPEN-ANGLE GLAUCOMA (POAG) Yu E, Hay J, Varma R, Globe D, University of Southern California, Los Angeles, CA, USA

GASTROINTESTINAL DISORDERS (PGI)
PGI1	EFFECTS ON HEALTHCARE CONTACTS AND DAYS ABSENT FROM WORK WITH BUDESONIDE CIR CAPSULES IN THE MAINTENANCE TREATMENT OF CROHN'S DISEASE IN A US SETTING Ericsson K, Borg S, AstraZeneca R&D Lund, Lund, Sweden
PGI2	ALTERNATIVE MANAGEMENT STRATEGIES FOR DYSPEPSIA Wu EQ, Hay J, University of Southern California, Los Angeles, CA, USA
PGI3	A PROSPECTIVE, RANDOMIZED COST ANALYSIS OF MEPERIDINE AND MIDAZOLAM VERSUS PROPOFOL FOR COMPLEX UPPER ENDOSCOPY PROCEDURES Shermock KM, Vargo JJ, Zuccaro G, Maurer WG, Cleveland Clinic Foundation, Cleveland, OH, USA
PGI4	HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA REVEAL DIFFERENCES AMONG CLINICAL "RESPONDERS" Watson ME, Heath AT, Northcutt AR, GlaxoSmithKline, Research Triangle Park, NC, USA
PGI5	HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHN'S DISEASE Ericsson K1, Löfberg R2, Danielsson Å3, Floren CH4, Borg S1, 1AstraZeneca R&D Lund, Lund, Sweden; 2Karolinska Institute, Stockholm, Sweden; 3Umeå University Hospital, Umeå, Sweden; 4Lund University Hospital, Lund, Sweden
PGI6	COST-EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI ERADICATION TRIPLE THERAPY VERSUS CONVENTIONAL THERAPY FOR GASTRIC AND DUODENAL ULCERS IN JAPAN Ikeda S1, Tamamuro T1, Asaka M2, 1Keio University School of Medicine, Tokyo, Japan; 2Hokkaido University School of Medicine, Sapporo, Hokkaido, Japan
PGI7	BUDESONIDE CIR IS COST-EFFECTIVE IN MAINTENANCE THERAPY OF CROHN'S DISEASE IN FINLAND Ericsson K1, Karvonen AL2, Sintonen H3, Borg S1, 1AstraZeneca R&D Lund, Lund, Sweden; 2Tampere University Hospital, Tampere, Finland; 3University of Helsinki, Helsinki, Finland
PGI8	RAPID IMPACT OF RABEPRAZOLE ON SYMPTOM DISTRESS AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE Damiano A1, Adler E1, Siddique R2, Sloan S2, Bhattacharjya A2, 1Covance Health Economics and Outcomes Services Inc, Gaithersburg, MD, USA; 2Janssen Pharmaceutica Inc, Titusville, NJ, USA
PGI9	COST-EFFECTIVENESS OF 'TEST&TREAT' IN HELICOBACTER PYLORI INFECTED DYSPEPTIC PATIENTS IN A PRIMARY CARE SETTING Chen KS, Hay J, University of Southern California, Los Angeles, CA, USA
PGI10	IRRITABLE BOWEL SYNDROME COSTS SICKNESS FUNDS DM 2.8 BILLION PER YEAR Schultes HJ1, Guminski W2, Rosche U2, Ries B1, Pirk O3, 1Novartis Pharma, Nuremberg, Germany; 2I+G Gesundheitsforschung, Munich, Germany; 3Fricke & Pirk, Nuremberg, Germany
PGI11	CHARACTERIZATION AND MARKOV MODELING OF GASTROESOPHAGEAL REFLUX DISEASE STATES IN A LARGE HEALTHCARE PLAN Brelje T1, Heaton A1, Martin S1, Bhattacharjya A2, Dodd S2, Thornhill J2, 1Prime Therapeutics, Inc, Eagan, MN, USA; 2Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA
PGI12	ESTIMATING POTENTIAL UTILIZATION OF ESOMEPRAZOLE BY ASSESSING GERD SYMPTOM CONTROL ON TRADITIONAL PPI'S DeLattre ML, Schaefer M, Morreale AP, Plowman BK, VA San Diego Healthcare System, San Diego, CA, USA
PGI13	ANALYSIS OF THE LONG TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE Annemans L1, Moeremans K1, Rutgeerts P2, Lemmens L1, 1HEDM, Meise, Belgium; 2University of Louvain, Leuven, Belgium
PGI14	HOW IMPORTANT IS APPROPRIATE EMPIRICAL ANTIBIOTIC TREATMENT FOR INTRA-ABDOMINAL INFECTIONS? Davey P1, Libby G1, Hunter K1, Broomhall J1, Kofteridis D1, Steinke D1, Taylor E2, Yin D3, 1University of Dundee, Dundee, UK; 2Vale of Leven Hospital, Alexandria, UK; 3Merck & Co, Bridgewater, NJ, USA
PGI15	COMPUTERIZED ASSESSMENT OF COMPLICATIONS FOLLOWING COLORECTAL SURGERY Kroch E1, Azimuddin K2, Rosen L2, Reed JF2, 1Villanova University, Villanova, PA, USA; 2Lehigh Valley Hospital, Allentown, PA, USA
PGI16	ANALYSIS OF THE LONG TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE Annemans L1, Moeremans K1, Rutgeerts P2, Lemmens L1, 1HEDM, Meise, Belgium; 2University of Louvain, Leuven, Belgium
PGI17	COMPARISON OF GENERIC VERSUS DISEASE SPECIFIC TOOLS FOR THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CROHN'S DISEASE Wurtzbacher JD1, Gourley GK1, Reed PJ1, Gourley DR1, Solomon DK1, Haas JW2, 1University of Tennessee Health Science Center, Memphis, TN, USA; 2University of Tennessee, Knoxville, TN, USA
Sixth Annual International Meeting Main Page

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.